The comorbidity and co-medication profile of patients with progressive supranuclear palsy

Stephan Greten; Florian Wegner; Ida Jensen; Lea Krey; Sophia Rogozinski; Meret Fehring; Johanne Heine; Johanna Doll-Lee; Monika Pötter-Nerger; Molly Zeitzschel; Keno Hagena; David J. Pedrosa; Carsten Eggers; Katrin Bürk; Claudia Trenkwalder; Inga Claus; Tobias Warnecke; Patrick Süß; Jürgen Winkler; Doreen Gruber; Florin Gandor; Daniela Berg; Steffen Paschen; Joseph Classen; Elmar H. Pinkhardt; Jan Kassubek; Wolfgang H. Jost; Lars Tönges; Andrea A Kühn; Johannes Schwarz; Oliver Peters; Eman Dashti; Josef Priller; Eike J. Spruth; Patricia Krause; Annika Spottke; Anja Schneider; Aline Beyle; Okka Kimmich; Markus Donix; Robert Haussmann; Moritz Brandt; Elisabeth Dinter; Jens Wiltfang; Björn H. Schott; Inga Zerr; Mathias Bähr; Katharina Buerger; Daniel Janowitz; Robert Perneczky; Boris-Stephan Rauchmann; Endy Weidinger; Johannes Levin; Sabrina Katzdobler; Emrah Düzel; Wenzel Glanz; Stefan Teipel; Ingo Kilimann; Johannes Prudlo; Thomas Gasser; Kathrin Brockmann; Daniel C. Hoffmann; Thomas Klockgether; Olaf Krause; Johannes Heck; Günter U. Höglinger; Martin Klietz

doi:10.1007/s00415-023-12006-4

The comorbidity and co-medication profile of patients with progressive supranuclear palsy

Stephan Greten, Florian Wegner, Ida Jensen, Lea Krey, Sophia Rogozinski, Meret Fehring, Johanne Heine, Johanna Doll-Lee, Monika Pötter-Nerger, Molly Zeitzschel, Keno Hagena, David J. Pedrosa, Carsten Eggers, Katrin Bürk, Claudia Trenkwalder, Inga Claus, Tobias Warnecke, Patrick Süß, Jürgen Winkler, Doreen GruberFlorin Gandor, Daniela Berg, Steffen Paschen, Joseph Classen, Elmar H. Pinkhardt, Jan Kassubek, Wolfgang H. Jost, Lars Tönges, Andrea A Kühn, Johannes Schwarz, Oliver Peters, Eman Dashti, Josef Priller, Eike J. Spruth, Patricia Krause, Annika Spottke, Anja Schneider, Aline Beyle, Okka Kimmich, Markus Donix, Robert Haussmann, Moritz Brandt, Elisabeth Dinter, Jens Wiltfang, Björn H. Schott, Inga Zerr, Mathias Bähr, Katharina Buerger, Daniel Janowitz, Robert Perneczky, Boris-Stephan Rauchmann, Endy Weidinger, Johannes Levin, Sabrina Katzdobler, Emrah Düzel, Wenzel Glanz, Stefan Teipel, Ingo Kilimann, Johannes Prudlo, Thomas Gasser, Kathrin Brockmann, Daniel C. Hoffmann, Thomas Klockgether, Olaf Krause, Johannes Heck, Günter U. Höglinger, Martin Klietz

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

3 Downloads (Pure)

Abstract

Background Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.

Objectives To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.

Methods Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug–drug interactions were evaluated using AiDKlinik®.

Results In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug–drug interactions was higher in PSP patients, especially severe and moderate interactions.

Conclusions PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.

Original language	English
Pages (from-to)	782-793
Number of pages	12
Journal	Journal of Neurology
Volume	271
Issue number	2
DOIs	https://doi.org/10.1007/s00415-023-12006-4
Publication status	Published - Feb 2024
Externally published	Yes

Bibliographical note

Copyright the Author(s) 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

Humans
Aged
Supranuclear Palsy, Progressive/drug therapy
Neurodegenerative Diseases/epidemiology
Cross-Sectional Studies
Comorbidity
Polypharmacy
Comorbidities
Progressive supranuclear palsy
Drug–drug interactions

Access to Document

10.1007/s00415-023-12006-4Licence: CC BY

Publisher version (open access)Final published version, 1.07 MBLicence: CC BY

Cite this

Greten, S., Wegner, F., Jensen, I., Krey, L., Rogozinski, S., Fehring, M., Heine, J., Doll-Lee, J., Pötter-Nerger, M., Zeitzschel, M., Hagena, K., Pedrosa, D. J., Eggers, C., Bürk, K., Trenkwalder, C., Claus, I., Warnecke, T., Süß, P., Winkler, J., ... Klietz, M. (2024). The comorbidity and co-medication profile of patients with progressive supranuclear palsy. Journal of Neurology, 271(2), 782-793. https://doi.org/10.1007/s00415-023-12006-4

@article{ba40dfb8e3794c6da19b2ff89e3478cc,

title = "The comorbidity and co-medication profile of patients with progressive supranuclear palsy",

abstract = "Background Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.Objectives To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.Methods Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug–drug interactions were evaluated using AiDKlinik{\textregistered}.Results In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug–drug interactions was higher in PSP patients, especially severe and moderate interactions.Conclusions PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.",

keywords = "Humans, Aged, Supranuclear Palsy, Progressive/drug therapy, Neurodegenerative Diseases/epidemiology, Cross-Sectional Studies, Comorbidity, Polypharmacy, Comorbidities, Progressive supranuclear palsy, Drug–drug interactions",

author = "Stephan Greten and Florian Wegner and Ida Jensen and Lea Krey and Sophia Rogozinski and Meret Fehring and Johanne Heine and Johanna Doll-Lee and Monika P{\"o}tter-Nerger and Molly Zeitzschel and Keno Hagena and Pedrosa, \{David J.\} and Carsten Eggers and Katrin B{\"u}rk and Claudia Trenkwalder and Inga Claus and Tobias Warnecke and Patrick S{\"u}{\ss} and J{\"u}rgen Winkler and Doreen Gruber and Florin Gandor and Daniela Berg and Steffen Paschen and Joseph Classen and Pinkhardt, \{Elmar H.\} and Jan Kassubek and Jost, \{Wolfgang H.\} and Lars T{\"o}nges and K{\"u}hn, \{Andrea A\} and Johannes Schwarz and Oliver Peters and Eman Dashti and Josef Priller and Spruth, \{Eike J.\} and Patricia Krause and Annika Spottke and Anja Schneider and Aline Beyle and Okka Kimmich and Markus Donix and Robert Haussmann and Moritz Brandt and Elisabeth Dinter and Jens Wiltfang and Schott, \{Bj{\"o}rn H.\} and Inga Zerr and Mathias B{\"a}hr and Katharina Buerger and Daniel Janowitz and Robert Perneczky and Boris-Stephan Rauchmann and Endy Weidinger and Johannes Levin and Sabrina Katzdobler and Emrah D{\"u}zel and Wenzel Glanz and Stefan Teipel and Ingo Kilimann and Johannes Prudlo and Thomas Gasser and Kathrin Brockmann and Hoffmann, \{Daniel C.\} and Thomas Klockgether and Olaf Krause and Johannes Heck and H{\"o}glinger, \{G{\"u}nter U.\} and Martin Klietz",

note = "Copyright the Author(s) 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2024",

month = feb,

doi = "10.1007/s00415-023-12006-4",

language = "English",

volume = "271",

pages = "782--793",

journal = "Journal of Neurology",

issn = "0340-5354",

publisher = "Springer, Springer Nature",

number = "2",

}

Greten, S, Wegner, F, Jensen, I, Krey, L, Rogozinski, S, Fehring, M, Heine, J, Doll-Lee, J, Pötter-Nerger, M, Zeitzschel, M, Hagena, K, Pedrosa, DJ, Eggers, C, Bürk, K, Trenkwalder, C, Claus, I, Warnecke, T, Süß, P, Winkler, J, Gruber, D, Gandor, F, Berg, D, Paschen, S, Classen, J, Pinkhardt, EH, Kassubek, J, Jost, WH, Tönges, L, Kühn, AA, Schwarz, J, Peters, O, Dashti, E, Priller, J, Spruth, EJ, Krause, P, Spottke, A, Schneider, A, Beyle, A, Kimmich, O, Donix, M, Haussmann, R, Brandt, M, Dinter, E, Wiltfang, J, Schott, BH, Zerr, I, Bähr, M, Buerger, K, Janowitz, D, Perneczky, R, Rauchmann, B-S, Weidinger, E, Levin, J, Katzdobler, S, Düzel, E, Glanz, W, Teipel, S, Kilimann, I, Prudlo, J, Gasser, T, Brockmann, K, Hoffmann, DC, Klockgether, T, Krause, O, Heck, J, Höglinger, GU & Klietz, M 2024, 'The comorbidity and co-medication profile of patients with progressive supranuclear palsy', Journal of Neurology, vol. 271, no. 2, pp. 782-793. https://doi.org/10.1007/s00415-023-12006-4

TY - JOUR

T1 - The comorbidity and co-medication profile of patients with progressive supranuclear palsy

AU - Greten, Stephan

AU - Wegner, Florian

AU - Jensen, Ida

AU - Krey, Lea

AU - Rogozinski, Sophia

AU - Fehring, Meret

AU - Heine, Johanne

AU - Doll-Lee, Johanna

AU - Pötter-Nerger, Monika

AU - Zeitzschel, Molly

AU - Hagena, Keno

AU - Pedrosa, David J.

AU - Eggers, Carsten

AU - Bürk, Katrin

AU - Trenkwalder, Claudia

AU - Claus, Inga

AU - Warnecke, Tobias

AU - Süß, Patrick

AU - Winkler, Jürgen

AU - Gruber, Doreen

AU - Gandor, Florin

AU - Berg, Daniela

AU - Paschen, Steffen

AU - Classen, Joseph

AU - Pinkhardt, Elmar H.

AU - Kassubek, Jan

AU - Jost, Wolfgang H.

AU - Tönges, Lars

AU - Kühn, Andrea A

AU - Schwarz, Johannes

AU - Peters, Oliver

AU - Dashti, Eman

AU - Priller, Josef

AU - Spruth, Eike J.

AU - Krause, Patricia

AU - Spottke, Annika

AU - Schneider, Anja

AU - Beyle, Aline

AU - Kimmich, Okka

AU - Donix, Markus

AU - Haussmann, Robert

AU - Brandt, Moritz

AU - Dinter, Elisabeth

AU - Wiltfang, Jens

AU - Schott, Björn H.

AU - Zerr, Inga

AU - Bähr, Mathias

AU - Buerger, Katharina

AU - Janowitz, Daniel

AU - Perneczky, Robert

AU - Rauchmann, Boris-Stephan

AU - Weidinger, Endy

AU - Levin, Johannes

AU - Katzdobler, Sabrina

AU - Düzel, Emrah

AU - Glanz, Wenzel

AU - Teipel, Stefan

AU - Kilimann, Ingo

AU - Prudlo, Johannes

AU - Gasser, Thomas

AU - Brockmann, Kathrin

AU - Hoffmann, Daniel C.

AU - Klockgether, Thomas

AU - Krause, Olaf

AU - Heck, Johannes

AU - Höglinger, Günter U.

AU - Klietz, Martin

N1 - Copyright the Author(s) 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2024/2

Y1 - 2024/2

N2 - Background Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.Objectives To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.Methods Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug–drug interactions were evaluated using AiDKlinik®.Results In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug–drug interactions was higher in PSP patients, especially severe and moderate interactions.Conclusions PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.

AB - Background Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.Objectives To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.Methods Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug–drug interactions were evaluated using AiDKlinik®.Results In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug–drug interactions was higher in PSP patients, especially severe and moderate interactions.Conclusions PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.

KW - Humans

KW - Aged

KW - Supranuclear Palsy, Progressive/drug therapy

KW - Neurodegenerative Diseases/epidemiology

KW - Cross-Sectional Studies

KW - Comorbidity

KW - Polypharmacy

KW - Comorbidities

KW - Progressive supranuclear palsy

KW - Drug–drug interactions

UR - https://www.scopus.com/pages/publications/85173912975

U2 - 10.1007/s00415-023-12006-4

DO - 10.1007/s00415-023-12006-4

M3 - Article

C2 - 37803149

SN - 0340-5354

VL - 271

SP - 782

EP - 793

JO - Journal of Neurology

JF - Journal of Neurology

IS - 2

ER -

The comorbidity and co-medication profile of patients with progressive supranuclear palsy

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this